Literature DB >> 29151176

Adherence to TKI in CML patients: more than reports.

Jessica de O Souza1, Fernanda de O Busato2, Isadora Duarte Santos Frota3, Daniel Santos Neves4, Marcelo Renan de Deus Santos4, David N Olivieri5, Carlos E Tadokoro6,7,8,9,10.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29151176     DOI： 10.1007/s00520-017-3979-y

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  6 in total

Review 1.  Discovery of the Philadelphia chromosome: a personal perspective.

Authors:  Peter C Nowell
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

2.  How to report adherence to treatment as clinically relevant data-making a case of CML and TKI.

Authors:  Lucas Miyake Okumura
Journal:  Support Care Cancer       Date:  2017-07-11       Impact factor: 3.603

3.  The role of clinical pharmacists in treatment adherence: fast impact in suppression of chronic myeloid leukemia development and symptoms.

Authors:  Silmara Mendes Martins Moulin; Frederico Jacob Eutrópio; Jessica de Oliveira Souza; Fernanda de Oliveira Busato; David N Olivieri; Carlos Eduardo Tadokoro
Journal:  Support Care Cancer       Date:  2016-11-19       Impact factor: 3.603

4.  Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a Brazilian single-center cohort.

Authors:  Maria H de Almeida; Katia B B Pagnano; Afonso C Vigorito; Irene Lorand-Metze; Carmino A de Souza
Journal:  Acta Haematol       Date:  2013-01-25       Impact factor: 2.195

5.  Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment.

Authors:  Lucas M Okumura; Valquíria D Antunes; Karina S Aguiar; Tatiane Farias; Vânia M Andrzejevski; Vaneuza M Funke
Journal:  Pharm Pract (Granada)       Date:  2015-06-15

6.  Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experience.

Authors:  Beatriz Felicio Ribeiro; Eliana C M Miranda; Dulcinéia Martins de Albuquerque; Márcia T Delamain; Gislaine Oliveira-Duarte; Maria Helena Almeida; Bruna Vergílio; Rosana Antunes da Silveira; Vagner Oliveira-Duarte; Irene Lorand-Metze; Carmino A De Souza; Katia B B Pagnano
Journal:  Clinics (Sao Paulo)       Date:  2015-08       Impact factor: 2.365
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.